Caspase 8 (CASP8) Human shRNA Plasmid Kit (Locus ID 841)
CAT#: TG305635
CASP8 - Human, 4 unique 29mer shRNA constructs in retroviral GFP vector, 5µg of each construct provided
Need custom shRNA service?
Get a free quote
CNY 4,790.00
货期*
现货
规格
Cited in 1 publication. |
Product images
经常一起买 (2)
Specifications
Product Data | |
Product Name | Caspase 8 (CASP8) Human shRNA Plasmid Kit (Locus ID 841) |
Locus ID | 841 |
UniProt ID | Q14790 |
Synonyms | ALPS2B; CAP4; Casp-8; FLICE; MACH; MCH5 |
Vector | pGFP-V-RS |
Format | Retroviral plasmids |
Kit Components | CASP8 - Human, 4 unique 29mer shRNA constructs in retroviral GFP vector(Gene ID = 841). 5µg purified plasmid DNA per construct29-mer scrambled shRNA cassette in pGFP-V-RS Vector, TR30013, included for free. |
RefSeq | NM_001080124, NM_001080125, NM_001228, NM_033355, NM_033356, NM_033357, NM_033358, NR_111983, NM_033356.1, NM_033356.2, NM_033356.3, NM_001080125.1, NM_033355.1, NM_033355.2, NM_033355.3, NM_033358.2, NM_033358.3, NM_001080124.1, NM_001228.1, NM_001228.2, NM_001228.3, NM_001228.4, BC010390, BC017031, BC028223, BC068050, NM_001080125.2, NM_033358.4, NM_033356.4, NM_001080124.2 |
Summary | This gene encodes a member of the cysteine-aspartic acid protease (caspase) family. Sequential activation of caspases plays a central role in the execution-phase of cell apoptosis. Caspases exist as inactive proenzymes composed of a prodomain, a large protease subunit, and a small protease subunit. Activation of caspases requires proteolytic processing at conserved internal aspartic residues to generate a heterodimeric enzyme consisting of the large and small subunits. This protein is involved in the programmed cell death induced by Fas and various apoptotic stimuli. The N-terminal FADD-like death effector domain of this protein suggests that it may interact with Fas-interacting protein FADD. This protein was detected in the insoluble fraction of the affected brain region from Huntington disease patients but not in those from normal controls, which implicated the role in neurodegenerative diseases. Many alternatively spliced transcript variants encoding different isoforms have been described, although not all variants have had their full-length sequences determined. [provided by RefSeq, Jul 2008] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Citations (1)
The use of this RNAi has been cited in the following citations: |
---|
Regression of apoptosis-resistant colorectal tumors by induction of necroptosis in mice
,He, GW;Günther, C;Thonn, V;Yu, YQ;Martini, E;Buchen, B;Neurath, MF;Stürzl, M;Becker, C;,
J. Exp. Med.
,PubMed ID 28476895
[CASP8]
|
Documents
Product Manuals |
FAQs |
SDS |
Customer
Reviews
Loading...